Search: WFRF:(Hellstrom Lindberg E) >
A validated decisio...
-
Hellstrom-Lindberg, E.Karolinska Institutet,Hellström-Lindberg, E., Department of Medicine, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden, Department of Medicine, Karolinska Institute, Huddinge University Hospital, 141 86 Stockholm, Sweden
(author)
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor : Significant effects on quality of life
- Article/chapterEnglish2003
Publisher, publication year, extent ...
-
2003-03-18
-
Wiley,2003
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:liu-46701
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-46701URI
-
https://doi.org/10.1046/j.1365-2141.2003.04153.xDOI
-
https://lup.lub.lu.se/record/316320URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:1929798URI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-65845URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
We have published previously a prototype of a decision model for anaemic patients with myelodysplastic syndromes (MDS), in which transfusion need and serum erythropoietin (S-Epo) were used to define three groups with different probabilities of erythroid response to treatment with granulocyte colony-stimulating factor (G-CSF) + Epo. S-Epo = 500 U/l and a transfusion need of < 2 units/month predicted a high probability of response to treatment, S-Epo > 500 U/l and =2 units/month for a poor response, whereas the presence of only one negative prognostic marker predicted an intermediate response. A total of 53 patients from a prospective study were included in our evaluation sample. Patients with good or intermediate probability of response were treated with G-CSF + Epo. The overall response rate was 42% with 28.3% achieving a complete and 13.2% a partial response to treatment. The response rates were 61% and 14% in the good and intermediate predictive groups respectively. The model retained a significant predictive value in the evaluation sample (P < 0.001). Median duration of response was 23 months. Scores for global health and quality of life (QOL) were significantly lower in MDS patients than in a reference population, and fatigue and dyspnoea was significantly more prominent. Global QOL improved in patients responding to treatment (P = 0.01). The validated decision model defined a subgroup of patients with a response rate of 61% (95% confidence interval 48-74%) to treatment with G-CSF + Epo. The majority of these patients have shown complete and durable responses.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Gulbrandsen, N.Department of Haematology, Ullevål Hospital, Oslo, Norway
(author)
-
Lindberg, G.Karolinska Institutet,Department of Medicine, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
(author)
-
Ahlgren, T.Depts. Med./Haematol. the Hospitals, Malmö, Sweden
(author)
-
Dahl, I.M.S.Depts. Med./Haematol. the Hospitals, Tromsö, Norway
(author)
-
Dybedal, I.Depts. Med./Haematol. the Hospitals, Trondheim, Norway
(author)
-
Grimfors, G.Uppsala universitet,Institutionen för medicinska vetenskaper,Blodsjukdomar
(author)
-
Hesse-Sundin, E.Karolinska Hospital, Eskilstuna, Sweden
(author)
-
Hjorth, M.Karolinska Hospital, Lidköping, Sweden
(author)
-
Kanter-Lewensohn, L.Karolinska Institutet,Department of Pathology, Karolinska Hospital, Stockholm, Sweden
(author)
-
Linder, O.Karolinska Hospital, Örebro, Sweden
(author)
-
Luthman, M.St. Göran Hospital, Stockholm, Sweden
(author)
-
Lofvenberg, E.Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi,Onko
(author)
-
Oberg, G.Öberg, G., St. Göran Hospital, Uppsala, Sweden
(author)
-
Porwit-MacDonald, A.Karolinska Institutet,Department of Pathology, Karolinska Hospital, Stockholm, Sweden
(author)
-
Rådlund, AndersÖstergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Onkologiska kliniken US(Swepub:liu)andra74
(author)
-
Samuelsson Johannesson, JannicaKarolinska Institutet,Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Southern Hospital, Stockholm, Sweden(Swepub:lu)med-jsl
(author)
-
Tangen, J.M.Department of Haematology, Ullevål Hospital, Oslo, Norway
(author)
-
Winquist, I.Southern Hospital, Lund, Sweden
(author)
-
Wisloff, F.Department of Haematology, Ullevål Hospital, Oslo, Norway
(author)
-
Karolinska InstitutetHellström-Lindberg, E., Department of Medicine, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden, Department of Medicine, Karolinska Institute, Huddinge University Hospital, 141 86 Stockholm, Sweden
(creator_code:org_t)
Related titles
-
In:British Journal of Haematology: Wiley120, s. 1037-0007-10481365-2141
-
In:Br J Haematol: Wiley120, s. 1037-
Internet link
Find in a library
To the university's database
- By the author/editor
-
Hellstrom-Lindbe ...
-
Gulbrandsen, N.
-
Lindberg, G.
-
Ahlgren, T.
-
Dahl, I.M.S.
-
Dybedal, I.
-
show more...
-
Grimfors, G.
-
Hesse-Sundin, E.
-
Hjorth, M.
-
Kanter-Lewensohn ...
-
Linder, O.
-
Luthman, M.
-
Lofvenberg, E.
-
Oberg, G.
-
Porwit-MacDonald ...
-
Rådlund, Anders
-
Samuelsson Johan ...
-
Tangen, J.M.
-
Winquist, I.
-
Wisloff, F.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Hematology
- Articles in the publication
-
British Journal ...
- Br J Haematol
- By the university
-
Linköping University
-
Lund University
-
Karolinska Institutet
-
Uppsala University